Should You or Shouldn't You PSA Controversy?
For
the last 20 years PSA test have been suggested for all men over 50 years old. A
PSA test is a blood test that is used to find the level of prostate-specific
antigens in the blood stream. Abnormal amounts of this antigen can represent
the onset prostate cancer. This practice has been the standard, but new data
and research is showing that mass PSA testing doesn't have any effect on the
death rate of men who have prostate cancer. The controversy with PSA testing is
that they may result in overzealous treatment that can leave men infertile or
impotent. Some findings also say that the cancers that are found through PSA
might find slow growing cancer that takes decades to develop, and that most men
within this age range would die of natural causes or some other disease before
this slow growing prostate cancer will have time to develop. The new studies
show that men who wait until they have actual symptoms of prostate cancer share
the same exact mortality rate as men who have had routine PSA tests.
As
a medical billing test this has direct implications. Insurance companies and
HMO's may no longer pay for PSA testing and speculative biopsies. Urologist and
Primary care Doctor's might have to stop suggesting these test and procedures
for their patients because they will no longer be covered under future
insurance plan. Getting doctors paid for these services will become difficult.
The research behind these new findings followed over 70,000 men 50 years and older
and this test are said to have very little use. One rebuttal to these findings
might be the constant lower death rate from prostate cancer. Deaths from
prostate cancer decrease an average of 4% every year. One might posit that PSA
test might not help an aggregate of men, but the test is worth giving because
it helps a small amount of men survive prostate cancer.
Instead
of recommending PSA testing for all men, Doctors might want to start taking
advantage of Digital Rectum Exams. These exams can be performed less frequently
and will still provide early detection of tumor growth without all the false
flags that PSA testing gives. Digital Rectum Exams will still be billable to
insurance companies and HMO. The key is finding out what is best for the patient
and secondly what the insurance companies and HMO's will actually pay for. It
is unfortunate that health care is such a business, but medical billing
services must know what they can actually bill. What we hope to see are a list
of services, test, and procedures that physicians are allowed to give.
These
changes have not yet been put in place, but many patients are doing their own
due diligence and are learning about the unreliability of PSA test. There might
also be a group of patients who demand these tests and procedures. The world of prostate screening is changes - not much for the better, but towards the truth.
We hope to see new procedure that helps save more lives.